Showing results (2481-2490 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 11, 2017
Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I studyHideo Saka, Chiyoe Kitagawa, Yoshihito Kogure, et al.
Investigational New Drugs|May 6, 2008
Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell cultureMario Luiz Conte da Frota, Elizandra Braganhol, Andrés Delgado Canedo, et al.
Investigational New Drugs|April 3, 2014
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancerJohanna C Bendell, Heinz-Josef Lenz, Theresa Ryan, et al.
Investigational New Drugs|April 4, 2014
Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcomaTakafumi Ueda, Shigeki Kakunaga, Masashi Ando, et al.
Investigational New Drugs|April 11, 2014
Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulationPatrick T Grogan, Jann N Sarkaria, Barbara N Timmermann, et al.
Investigational New Drugs|March 28, 2014
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancerArun A Azad, Emma K Beardsley, Sebastian J Hotte, et al.
Investigational New Drugs|April 26, 2014
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapyMehmet Asim Bilen, Jean-Bernard Durand, Lacey McQuinn, et al.
Investigational New Drugs|April 26, 2014
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancerMaha Hussain, Michael A Carducci, Susan Slovin, et al.
Investigational New Drugs|May 14, 2014
The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathwaysSusi Barollo, Loris Bertazza, Enke Baldini, et al.
Investigational New Drugs|April 1, 2014
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancerSuqin He, Donald L Smith, Manuel Sequeira, et al.
Pageof 372